Back to search

Article

PARP1 catalytic domain mutations drive high-level resistance to saruparib while preserving DNA damage response vulnerabilities

2026-05-13

Abstract excerpt

Clinical poly (ADP)-ribose polymerase (PARP) inhibitors (PARPi) are limited by toxicities associated with inhibition of multiple PARP family proteins and acquired resistance. As PARP1-specific inhibitors, like saruparib (AZD5305), move toward standard-of-care status for BRCA and HR-deficient cancers replacing less specific PARPi, defining mechanisms of intrinsic and acquired resistance is essential for developing...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4b7bf4c2-a502-51ab-a5f1-b869b19fd1ac
DOI
10.64898/2026.05.08.723870
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
PARP1 catalytic domain mutations drive high-level resistance to saruparib while preserving DNA damage response vulnerabilitiesDOI 10.64898/2026.05.08.723870
Select a neighboring publication to make it the new centre.